Literature DB >> 7225141

Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.

J Kapuscinski, Z Darzynkiewicz, F Traganos, M R Melamed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7225141     DOI： 10.1016/0006-2952(81)90083-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  25 in total

1.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.

Authors:  H Osswald; M Youssef
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

4.  DNA sequence specificity of mitoxantrone.

Authors:  C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

5.  Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation.

Authors:  G Fox; O Popanda; L Edler; H W Thielmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study.

Authors:  H G Eichler; R Mader; B Blöchl-Daum; G Steger; H Rainer
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Increased accessibility of bases in DNA upon binding of acridine orange.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Nucleic Acids Res       Date:  1983-11-11       Impact factor: 16.971

9.  Development of mitoxantrone.

Authors:  R J White; F E Durr
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

10.  Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.

Authors:  V Heinemann; D Murray; R Walters; R E Meyn; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.